The Latest DURYSTA™ Glaucoma Treatment
Board-Certified Ophthalmologist, Dr. Savak Teymoorian of Harvard Eye Associates, assisted in the research and development of a new glaucoma drug.
Laguna Hills, Ca.—Harvard Eye Associates is able to offer patients dealing with glaucoma a revolutionary new eye treatment that was researched and developed by one of its own board-certified ophthalmologists, Dr. Savak Teymoorian.
Dr. Teymoorian, an experienced cataract and glaucoma surgeon, helped develop a new and innovative glaucoma drug, called DURYSTA™. DURYSTA™ is the only FDA-approved treatment that allows glaucoma patients to take one medication to treat their glaucoma instead of using multiple eye drops.
Glaucoma is a progressive and degenerative disease of the optic nerve, that when left untreated, leads to vision loss. Over three million Americans have glaucoma, but many don’t have any symptoms. Regular eye exams to check for glaucoma are essential. There is no cure for glaucoma, but it can be managed with the help of a qualified ophthalmologist, including the doctors at Harvard Eye Associates.
“Glaucoma care is entering into a wonderful stage where finally we can provide our patients with proactive, as opposed to reactive, care,” said Dr. Teymoorian. “We no longer need to settle for doing just enough to get by with the hopes that things will work out. Instead, we have the tools in place to do better, which can dramatically improve our patients’ quality of life. DURYSTA™ is a perfect example of this paradigm shift.”
Patients using Durysta no longer have to worry about administering a series of eye drops each day. This is especially important for elderly patients or those who have difficulty inserting eye drops properly. DURYSTA™ is a tiny dissolvable implant that releases medicine to reduce the high eye pressure caused by glaucoma. It is given to patients in a short, outpatient procedure. Harvard Eye Associates is one of the first ophthalmology practices in the nation that is able to administer this new, cutting-edge treatment.
Patients with glaucoma experience the buildup of pressure inside the eye, known as intraocular pressure. When fluid in the eye drains properly, eye pressure remains at a normal level. But when it cannot drain properly, it builds up in the eye, increasing the pressure against the optic nerve, which can ultimately damage it and lead to vision loss. Elevated eye pressure is a major risk factor for vision loss associated with glaucoma. DURYSTA™ reduces eye pressure by seamlessly releasing medicine directly into the eye to reduce eye pressure.
To see if Durysta is right for you, and to discuss treatment options to manage your glaucoma, or to have a glaucoma test, contact Harvard Eye Associates at www.harvardeye.com or call 949-951-2020 to make an appointment. Glaucoma risk factors include heredity, being African-American, Hispanic, or Asian-American; having certain eye conditions including farsightedness or nearsightedness; taking steroid medications for a long time, being over 40, having thin corneas, having medical conditions that include high blood pressure, diabetes, heart disease or migraines; having had an eye injury, or having certain autoimmune diseases such as multiple sclerosis, lupus, or sickle cell anemia.
It is important for patients seeking treatment for glaucoma or other eye conditions to be treated by qualified ophthalmologists, including Dr. Teymoorian. Dr. Teymoorian was recently voted one of Orange County’s top doctors. He is a cataract and glaucoma specialist who completed his fellowship at Stanford University and is one of the leading administrators of DURYSTA™. Harvard Eye Associates, with three locations throughout Orange County, is a multi-specialty ophthalmology practice with experienced surgeons who bring patients the most advanced treatments in medical and surgical eye care.
DURYSTA™ is a breakthrough for patients who have difficulty administering eye drops and need an alternative option. Harvard Eye Associates is proud to be a physician’s practice that contributes to our patients’ well-being by offering them new ways to preserve their vision.